Catalog No.
Product Name
Application
Product Information
Product Citation
-
Gamma-secretase inhibitor
BMS-708163 is an oral gamma secretase inhibitor designed for selective inhibition of amyloid beta synthesis. -
Neuroprotectant
Dimebon dihydrochloride is a non-selective antihistamine that displays cognitive enhancing abilities. -
Gamma-secretase inhibitor
RO4929097 is an orally bioavailable, small-molecule gamma secretase (GS) inhibitor with an IC50 of 4 nM.- Hirosumi Tamura, .et al. , Oncol Rep, 2018, Aug; 40(2): 635-646 PMID: 29917168
-
Amyloid-β production inhibitor
gamma-Secretase Modulators (Amyloid-β production inhibitor) is a Amyloid-β production inhibitor. gamma-Secretase Modulators is useful for Alzheimer's disease. -
amyloid β42 inhibitor
Ro 90-7501 is an inhibitor of amyloid β42 (Aβ42) fibril assembly; reduces Aβ42-induced toxicity (EC50 = 2 μM). - alpha-Amyloid Precursor Protein Modulator is a cell-permeable benzolactam derived PKC activator (Ki = 11.9 nM for PKCα) that efficiently enhances non-amyloidogenic α-processing of amyloid precursor protein (APP) even at 100 nM in human fibroblas.
- Amyloid beta (Aβ or Abeta) is a peptide of 36-C43 amino acids that is processed from the Amyloid precursor protein. Amyloid β-Peptide (1-42) human is a 42-amino acid peptide which plays a key role in the pathogenesis of Alzheimer disease.
- Seda Onder, .et al. , Chem Biol Interact, 2022, Aug 25;363:110029 PMID: 35779611
- Seham S El-Hawary, .et al. , Food Funct, 2022, Sep 7;12(17):8078-8089 PMID: 34286787
- Zsolt Datki, .et al. , Int J Biol Macromol, 2022, Jan 7;201:262-269 PMID: 34999044
- Suresh K.Bowroju, .et al. , Bioorg Med Chem, 2021, 45:116311
- Zsolt Datki, .et al. , Ecotoxicol Environ Saf, 2021, Jan 15;208:111666 PMID: 33396176
- Amyloid b-peptide (42-1) (human), inactive control for Amyloid b (1-42) peptide.
- Amyloid b-Peptide (10-20) (human), soluble amyloid b-peptide fragment that is a substrate for gelatinase A/type IV collagenase/MMP-2 and APP secretase; cleaved between Lys16 and Leu17.
- Amyloid b-peptide (25-35) (human), fragment of human amyloid beta-peptide, functionally required for the neurotrophic and neurotoxic effects associated with Alzheimer's disease.
- Amyloid b-Peptide (12-28) (human), amyloid b-peptide fragment; minimum section required to bind to brain proteins.
- Amyloid b-Peptide (1-40) (human) is a peptide processed from the amyloid precursor protein (APP).
- Amyloid b-Peptide (1-43) (human), amyloid β peptide fragment. Highly toxic, showing higher neurotoxicity compared to Aβ40 and Aβ42.
- Beta-amyloid (1-11) (Abeta) is a peptide with the sequence H-{Asp}{Ala}{Glu}{Phe}{Arg}{His}{Asp}{Ser}{Gly}{Tyr}{Glu}-OH,which is processed from the Amyloid precursor protein.
- Beta-amyloid protein (A beta), a 39-43 amino acid peptide composed of a portion of the transmembrane domain and the extracellular domain of the amyloid precursor protein (APP), is also the principal component of amyloid.
-
glutaminyl cyclase inhibitor
Glutaminyl Cyclase Inhibitor 2 is a glutaminyl cyclase inhibitor with an IC50 of 1.23 μM. -
glutaminyl cyclase inhibitor
Glutaminyl Cyclase Inhibitor 1 is a glutaminyl cyclase inhibitor with an IC50 of 0.5 μM. -
RAGE inhibitor
Azeliragon (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression in patients with mild Alzheimer??s disease (AD). Azeliragon also can cross the blood-brain barrier (BBB).
